For reasons discussed above, we examined whether the significant CYP2E1-dependent AMPK activation (pAMPKα1) was associated with concurrent hepatic activation of the adiponectin-AMPK-FOXO-signaling, an event that could potentially delay NAFLD/NASH-onset. Here, ADIPOQ is linked to metabolic dysfunction-associated steatotic liver disease.